These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23717574)

  • 41. Low levels of glycoprotein 96 indicate a worse prognosis in early-stage hepatocellular carcinoma patients after hepatectomy.
    Ji F; Zhang Y; Zhu ZB; Guo Y; Shen SL; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP
    Hum Pathol; 2019 Apr; 86():193-202. PubMed ID: 30529751
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
    Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
    World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tissue microarray-based study of hepatocellular carcinoma validating SPIB as potential clinical prognostic marker.
    Ho YJ; Lin YM; Huang YC; Yeh KT; Lin LI; Lu JW
    Acta Histochem; 2016 Jan; 118(1):38-45. PubMed ID: 26610895
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma.
    Wu MT; He SY; Chen SL; Li LF; He ZQ; Zhu YY; He X; Chen H
    BMC Cancer; 2019 Jun; 19(1):538. PubMed ID: 31164099
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Upregulation of protein tyrosine phosphatase type IVA member 3 (PTP4A3/PRL-3) is associated with tumor differentiation and a poor prognosis in human hepatocellular carcinoma.
    Mayinuer A; Yasen M; Mogushi K; Obulhasim G; Xieraili M; Aihara A; Tanaka S; Mizushima H; Tanaka H; Arii S
    Ann Surg Oncol; 2013 Jan; 20(1):305-17. PubMed ID: 23064776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High expression of myofibrillogenesis regulator-1 predicts poor prognosis for patients with hepatocellular carcinoma after curative hepatectomy.
    Wang C; Xiang H; Si H; Guo D; Sun M
    Int J Clin Exp Pathol; 2015; 8(11):14818-23. PubMed ID: 26823810
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
    Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
    Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.
    Zhang N; Gu J; Yin L; Wu J; Du MY; Ding K; Huang T; He X
    Oncotarget; 2016 Dec; 7(49):81389-81401. PubMed ID: 27835609
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
    Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
    World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mastermind-like Transcriptional Coactivator 1 Overexpression Predicts Poor Prognosis in Human with Hepatocellular Carcinoma.
    Wang J; Zhang SM; Wu JM; Lu ZC; Yang JR; Wu HS; Chen H; Lin B; Xu RH; Cao TS
    Ann Clin Lab Sci; 2016 Sep; 46(5):502-7. PubMed ID: 27650617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma.
    Chen XQ; He JR; Wang HY
    Med Oncol; 2012 Sep; 29(3):1843-9. PubMed ID: 21987076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma.
    Wang JH; Wei W; Guo ZX; Shi M; Guo RP
    J Transl Med; 2015 Feb; 13():41. PubMed ID: 25638165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
    Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma.
    Kato H; Yoshida H; Taniguch H; Nomura R; Sato K; Suzuki I; Nakata R
    World J Gastroenterol; 2015 Dec; 21(46):13101-12. PubMed ID: 26673627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis.
    Ha SY; Kim JH; Yang JW; Kim J; Kim B; Park CK
    Cancer Res Treat; 2016 Jul; 48(3):1065-73. PubMed ID: 26511806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma.
    Yu L; Zhang J; Guo X; Li Z; Zhang P
    Cancer Epidemiol; 2014 Aug; 38(4):408-13. PubMed ID: 24923856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of NEDD9 in hepatocellular carcinoma and its clinical significance.
    Lu P; Wang ZP; Dang Z; Zheng ZG; Li X; Zhou L; Ding R; Yue SQ; Dou KF
    Oncol Rep; 2015 May; 33(5):2375-83. PubMed ID: 25812772
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overexpression of MTHFD1 in hepatocellular carcinoma predicts poorer survival and recurrence.
    Yu H; Wang H; Xu HR; Zhang YC; Yu XB; Wu MC; Jin GZ; Cong WM
    Future Oncol; 2019 May; 15(15):1771-1780. PubMed ID: 30997850
    [No Abstract]   [Full Text] [Related]  

  • 59. [Clinicopathological significance of ezrin and SIX1 protein expression in alpha fetoprotein-negative hepatocellular carcinoma].
    Kong J; Zhou X; Han L; Quan C; Cui X; Lin Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Feb; 32(2):236-9. PubMed ID: 26927385
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria.
    Ho SY; Liu PH; Hsu CY; Hsia CY; Huang YH; Su CW; Lei HJ; Lee RC; Hou MC; Huo TI
    Dig Dis Sci; 2020 Feb; 65(2):658-667. PubMed ID: 31659612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.